Top stories in hematology/oncology: COVID-19 and cancer, 'unprecedented’ declines in melanoma mortality
The top story in hematology/oncology last week focused on how oncology providers can protect “the most vulnerable” during the COVID-19 pandemic.
Another top story was about a recent study published in the American Journal of Public Health that showed the introduction of new treatments for metastatic melanoma has led to an “unprecedented” decline in mortality over the past few years.
Read these and more top stories in hematology/oncology below:
COVID-19 and cancer
As the COVID-19 pandemic intensifies across the United States, incidence among individuals with cancer remains relatively low. Read more.
Sharp declines in melanoma mortality 'unprecedented in cancer medicine'
The introduction and approval of new treatments for metastatic melanoma has led to significant declines in population-level mortality over the past several years, according to results of a retrospective study published in American Journal of Public Health. Read more.
Neoadjuvant chemotherapy may not expedite treatment for breast cancer
Neoadjuvant chemotherapy did not appear to expedite treatment compared with adjuvant chemotherapy for women with breast cancer, according to study findings published in Cancer Medicine. Read more.
Novel agent appears safe, effective for relapsed, refractory diffuse large B-cell lymphoma
The novel cereblon-modulating agent avadomide demonstrated preliminary clinical efficacy among patients with relapsed or refractory diffuse large B-cell lymphoma, according to results of a phase 1 study published in Blood. Read more.
FDA grants anti-BCMA CAR-T orphan drug designation for advanced multiple myeloma
The FDA granted orphan drug designation to CART-ddBCMA, a chimeric antigen receptor T-cell therapy, for the treatment of multiple myeloma, according to a press release from the manufacturer. Read more.